Agents and Actions

, Volume 21, Issue 3–4, pp 371–374 | Cite as

Inhibition of C5a-induced basophil degranulation by disodium cromoglycate

  • H. W. Golden
  • D. A. Iacuzio
  • I. G. Otterness
Mediators of Acute Inflammation

Abstract

Injection of purified porcine C5a into 24-hr basophil-rich cutaneous basophil hypersensitivity sites in the dose range 10−12–10−10 moles/site produced cutaneous basophil anaphylaxis (CBA). The H1 anti-histamine antagonist mepyramine, given orally (3.0–30 mg/kg), inhibited the vasopermeability, but not the basophil degranulation, characteristic of CBA. The antiallergy agent disodium cromoglycate (DSCG), administered intravenously (3.0–30 mg/kg), inhibited vasopermeability and basophil degranulation. DSCG inhibition of mast cell degranulation was not important in the inhibition of CBA, since intact mast cells were found to be depleted at basophil-rich sites and absent at C5a-induced CBA sites from animals treated with DSCG.

C5a at 10−11 moles/site also induced vasopermeability and mast cell degranulation in normal guinea pig skin. Vasopermeability, but not mast cell degranulation, was inhibited by mepyramine at 30 mg/kg p.o. However, DSCG at 10 mg/kg i.v. failed to inhibit either the vasopermeability or the mast cell degranulation of this reaction. These results indicate that C5a induces the degranulation of both basophils and mast cells in the guinea pig, and that C5a-induced degranulation of basophils, but not mast cells, is inhibited by DSCG.

Keywords

Mast Cell Dose Range Disodium Cromoglycate Mast Cell Degranulation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    J. F. Regal, T. M. Hardy, F. B. Casey and L. W. Chakrin,C5a-induced histamine release. Int. Archs Allergy appl. Immun.72, 362–365 (1983).Google Scholar
  2. [2]
    K. B. Vancey, C. H. Hummer, L. Horvath, L. Drenfer, M. M. Frank and T. J. Lawley,Studies of human C5a as a mediator of inflammation in normal human skin. J. Clin. Invest.75, 486–495 (1985).PubMedGoogle Scholar
  3. [3]
    M. K. Church,Cromoglycate-like anti-allergic drugs: a review. Drugs of Today14 (7), 281–341 (1978).Google Scholar
  4. [4]
    M. K. Church,The role of basophils in asthma I. Sodium cromoglycate on histamine release and content. Clin. Allergy12, 223–228 (1982).PubMedGoogle Scholar
  5. [5]
    M. W. Greaves,The effect of disodium cromoglycate and other inhibitors on in vitro anaphylactic histamine release from guinea pig basophil leucocytes. Int Archs Allergy appl. Immun.36, 497–505 (1969).Google Scholar
  6. [6]
    H. W. Golden, G. L. Crean, D. A. Iacuzio and I. G. Otterness,Effect of disodium cromoglycate on cutaneous basophil anaphylaxis. J. Immunol.137, 1495–1503 (1986).PubMedGoogle Scholar
  7. [7]
    H. B. Richerson, H. F. Dvorak and S. Leskowitz,Cutaneous basophilic hypersensitivy: a new interpretation of the Jones-Mote reaction. J. Immunol.103, 1431–1434 (1969).PubMedGoogle Scholar
  8. [8]
    P. W. Askenase, R. De Bernardo, D. Tauben and M. Kashgarian,Cutaneous basophil anaphylaxis. Immediate vasopermeability increases and anaphylactic degranulation of basophils at delayed hypersensitivity reactions challenged with additional antigen. Immunology35, 741–755 (1978).PubMedGoogle Scholar
  9. [9]
    P. W. Askenase,Role of basophils, mast cells and vasoamines in hypersensitivity reactions with a delayed time course. Prog. Allergy23, 199–320 (1977).PubMedGoogle Scholar
  10. [10]
    M. A. Lett-Brown, D. O. Thueson and J. A. Grant,Dissociation between cutaneous basophil hypersensitivity and basophil sensitization. J. Immunol.129, 1262–1266 (1982).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1987

Authors and Affiliations

  • H. W. Golden
    • 1
  • D. A. Iacuzio
    • 1
  • I. G. Otterness
    • 1
  1. 1.Department of Immunology and Infectious DiseasesPfizer Central ResearchGrotonUSA

Personalised recommendations